Return to Track Selection

ALLERGY, IMMUNOLOGY AND RHEUMATOLOGY

9:15am-12:00pm
Mini Course
4011 Stem Cell Transplantation
Chair: Nancy Bunin, Children's Hospital of Philadelphia, Philadelphia, PA
This mini course will provide participants with an update on both the current status and future of stem cell transplant in pediatrics. Both malignant and non-malignant diseases will be addressed. Advances in graft engineering have made many of these advances possible, and this will be discussed in an overview of autologous stem cell transplant for solid tumors. Allogeneic stem cell transplant may be curative for some patients with hemoglobinopathies and metabolic diseases. Non-myeloablative approaches to hemoglobinopathies are a relatively novel approach, which may be curative without some of the short and long-term toxicities of a myeloablative regimen. Disease-specific characteristics that impact upon transplant outcome of patients with inherited metabolic storage disorders will be identified and discussed. Finally, the concepts of mesenchymal cell transplant and the future of mesenchymal cell transplant therapy will be summarized and discussed.

3:15pm-5:15pm
Topic Symposium
4200 Cloning and Embryonic Stem Cells
Chair: Judith Hall, University of British Columbia, Vancouver, Canada
There is enormous public interest in cloning and embryonic stem cells. This symposium will update the pediatric community on recent developments and raises a variety of policy and ethical issues.

3:15pm-5:15pm
Topic Symposium
4201 Innate Immunity
Chairs: Robert Modlin, University of California, Los Angeles, CA and David B. Lewis, Stanford University Medical Center, Stanford, CA
Most microorganisms encountered in daily life by normal, healthy children fail to cause disease. Rather, they are destroyed within minutes or hours by defense mechanisms that do not require priming or pre-existing experience. This symposium will highlight advances in our understanding of such innate immunity. Pattern recognition by Toll-like receptors, a novel antimicrobial protein and the role of natural killer cells in resistance to viral infection will be discussed.

8:00am-10:00am
Topic Symposium
5000 Inflammatory Disorders of the Cardiovascular System
Chair: James Bristow, University of California, San Francisco, CA
Inflammatory diseases of the cardiovascular system remain an important cause of morbidity and mortality in infants and children. While we do not think of these as genetic diseases, the application of powerful molecular genetic tools to these diseases has begun bear fruit. This session will provide an update on the pathogenesis of Kawasaki syndrome, the importance of viral infection and persistence of viral genomes in dilated cardiomyopathy and transplant rejection, and the mechanism of autoimmunity in congenital complete heart block.

8:00am-10:00am
Poster Symposium
5055 New Topics in Childhood Immunization Delivery
Chairs: Lance Rodewald and Judith S. Shaw

1:45pm-2:30pm
State of the Art Plenary
5590 Children as Victims of Bioterrorism: Protecting the Fragile Host
Chairs: Phyllis Dennery, Stanford University School of Medicine, Palo Alto, CA and Tina Lee Cheng, Johns Hopkins University School of Medicine, Baltimore, MD
With the recent world events and new threats of biowarfare, what should pediatricians know? Due to their size and physiology, children are at higher risk of injury from bioterrorism. This session will address the biology, clinical manifestations, and possible preventive strategies for likely biowarfare agents. The unique vulnerability of the child will be addressed.

2:00pm-4:00pm
State of the Art Plenary
5701 Children as Research Subjects: Ethical and Regulatory Issues
Chair: Myron Genel, Yale University School of Medicine, New Haven, CT
A number of highly publicized adverse events, including the death of two volunteers participating in non-therapeutic research, and the federal shutdown of research at many well-recognized academic institutions because of inadequate compliance with regulatory requirements have intensified scrutiny of the protection afforded to human subjects participating in research, including children. Furthermore a Maryland court has recently decreed that children cannot participate in research without the potential for direct benefit. As a consequence there has been increasing media attention and Congressional concern regarding the adequacy of institutional oversight and investigator attentiveness to established standards and regulations. In addition, new regulations issued under the Health Insurance Portability and Accountability Act of l996(HIPAA) threaten the capacity to conduct health services and outcomes research. These issues will be addressed in the 9th annual Public Policy Plenary Symposium in an interactive format intended to stimulate dialogue among the members of the panel and with the audience.

2:30pm-4:00pm
State of the Art Plenary
5704 Pediatric Research and the Human DNA Sequence: Approaching Defects of Host Defenses in the Genomic Era
Chairs: Jennifer M. Puck, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD and Stephen J. Chanock, National Cancer Institute, National Institutes of Health, Bethesda, MD
This session will provide a framework for understanding how genetics and genomics can accelerate progress in understanding defects in immunity and host defenses. Host defenses are used to demonstrate the general power of these technologies to elucidate pathogenetic mechanisms and predict disease susceptibility. This program will address classical and novel approaches to discovering genes underlying primary immunodeficiencies as well as characterization of modifier genes. A brief overview of the human genome, its structure, contents and relationship to genomes of other species will be presented in order to discuss current and future potential for understanding pediatric diseases and treatments. Emphasis will be placed on the continued prime importance of careful clinical observation, as well as the ethical and practical issues that genome science presents to society.

4:15pm-6:15pm
Topic Symposium
5802 The Molecular Basis of Clinical Manifestations of Infection
Chair: Philip Brunell, NIAID, National Institutes of Health, Bethesda, MD
This symposium will explore the molecular basis of the clinical expression of infectious diseases. The effect of a variety of different agents on the different organ systems of the human body will be presented by experts in their fields.

4:15pm-6:15pm
Platform Session
5907 Neonatal Immunity
Chair: Cynthia F. Bearer

4:15pm-6:15pm
Platform Session
5912 Pulmonology
Chair: Marie M. Egan

8:00am-10:00am
Platform Session
6051 Allergy, Immunology and Rheumatology: Cytokines and Signalling Molecules
Chairs: Terri H. Finkel and Crystal L. Mackall

8:00am-10:00am
Platform Session
6055 Infectious Diseases: Focus on Future Vaccines
Chairs: W. Paul Glezen and Neal A. Halsey

10:15am-12:00pm
Award
6150 SPR Presidential Plenary Session and Awards

SPR Presidential Plenary
Alan M. Krensky, Stanford University, Stanford, CA
Young Investigator Award
Andrew M. Scharenberg
David G. Nathan Award in Hematology–Oncology: Evaluation of IL-7 Signaling as a Therapeutic Target in a Transgenic Mouse Model: Effect of Rapamycin on Progenitor B Cell Malignancies
Valerie I. Brown
E. Mead Johnson Award for Research in Pediatrics
Nancy C. Andrews
Markus Grompe

– Allergy, Immunology and Rheumatology

8:00am-10:00am
Poster Symposium
7056 Inflammation in Lung Injury and Remodelling
Chairs: Carl T. D'Angio and David Warburton

8:45am-11:45am
Mini Course
7090 Controlling Asthma in the New Millennium
Chair: James S. Seidel, Harbor-UCLA Medical Center, UCLA School of Medicine, Torrance, CA
Although we have an understanding of the pathophysiology and treatment of asthma, the incidence, severity, and mortality from the disease is increasing. Twice in the past 10 years the National Heart Lung and Blood Institute has issued Guidelines for Diagnosis and Management of Asthma. These have not been widely adopted nor used. This mini course will explore the management of asthma in the emergency department and office setting and explore new methods to form care partnerships between practitioners, families and children to improve the care of asthma.

10:00am-11:45am
State of the Art Plenary
7201 Regenerative Medicine—From Stem Cells to Tissues
Chair: Clifford W. Bogue, Yale University School of Medicine, New Haven, CT
The potential to repair tissues and organs from stem cells has generated great excitement over the past year. Many diseases and pathological conditions, such as liver failure, spinal cord injury, Alzheimer’s disease and myocardial infarction, are now being viewed as potentially curable conditions through the use of stem cells. This session will focus on the developmental biology of stem cells and their amazing ability to give rise to many different fully-differentiated cell types. Investigators in the field of stem cell biology will discuss the potential advantages and limitations of using human embryonic stem cells, the plasticity of bone marrow-derived stem cells, and the therapeutic use of stem cells to regenerate damaged organs.

10:00am-11:45am
State of the Art Plenary
7202 Pharmacogenomics: Clinical and Therapeutic Implications
Chair: James Padbury, Women & Infant's Hospital of Rhode Island, Brown University, Providence, RI
The availability of high density sequence databases for large segments of the human genome has lead to the identification of single nucleotide polymorphisms (SNPs) in many important genes. If these SNPs occur in regulatory regions of important catalytic proteins, occur in binding domains of transmembrane signaling molecules or occur in the regulatory region of a gene, they can profoundly affect the function of that gene and on an individual patient basis. It has become clear these mechanisms account for some of the highly variable, once considered "idiosyncratic", responses to drug therapy. Pharmacogenomics is the study of how genetics affects responses to drugs. Pharmacogenomics holds the promise that drugs might one day be tailor-made for and adapted to each person's own genetic makeup. In this symposium speakers will present prominent examples of how pharmacogenomic implications affect the biology of disease and therapy from the fields of behavioral genetics and sychotherapeutics, cancer chemotherapy and the treatment of asthma. The perspectives presented will help the attendee understand a pathobiological and clinically sound approach to these disorders. The discussion will include basic science, clinical research and an industry perspective on this rapidly emerging area of importance.

1:45pm-3:45pm
Hot Topic
7701 The Cytokine Controversy
Chair: William Keenan, St. Louis University, St Louis, MO
Recent evidence suggests that the inflammatory response of the fetus can result in brain and lung injury pre and postnatally. Are cytokines the mediators of injury or mere bystanders? What therapeutic interventions can protect the neonate? Is it already too late by birth? The speakers will present both the pros and cons of the inflammatory response and a panel discussion will attempt to summarize available information and suggest questions and potential strategies for future research.

1:45pm-3:45pm
Hot Topic
7702 Disaster Preparedness: Beyond 9/11
Chairs: Tina L. Cheng, Johns Hopkins University School of Medicine, Baltimore, MD; Danelle Laraque, Mount Sinai School of Medicine, New York, NY; and Benard Dreyer, New York, NY
The impact of 9/11 and the public health aftermath have affected us personally and professionally. This session will address what the child health professional needs to know regarding disaster planning and preparedness. Speakers will review and provide updates on national and regional systems for emergency management and how those systems interact with local public health agencies, the pediatrician's role in the community's preparedness including what the school system, the pediatric office and the patient should be doing to prepare and respond, recognition and management of chemical and biologic agents of terrorism, and the psychological reactions to disaster and stress.

Disaster Planning and Preparedness for Child Health Professionals
George L. Foltin, New York University School of Medicine and Bellevue Hospital Center, New York, NY
Biologic Agents of Terrorism
Anne Fine, New York City Department of Health, New York, NY
Chemical Agents of Terrorism
Fred Henretig, University of Pennsylvania School of Medicine and Children's Hospital of Philadelphia, Philadelphia, PA
Helping Children Cope with Terrorism and Disasters
David J. Schonfeld, Yale University School of Medicine, New Haven, CT
Discussion